KR101616771B1 - 비면역원성의 소수성 단백질 나노입자의 형성방법 및 그 용도 - Google Patents

비면역원성의 소수성 단백질 나노입자의 형성방법 및 그 용도 Download PDF

Info

Publication number
KR101616771B1
KR101616771B1 KR1020107027648A KR20107027648A KR101616771B1 KR 101616771 B1 KR101616771 B1 KR 101616771B1 KR 1020107027648 A KR1020107027648 A KR 1020107027648A KR 20107027648 A KR20107027648 A KR 20107027648A KR 101616771 B1 KR101616771 B1 KR 101616771B1
Authority
KR
South Korea
Prior art keywords
nanoparticles
protein
solution
zein
jane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020107027648A
Other languages
English (en)
Korean (ko)
Other versions
KR20110036704A (ko
Inventor
오마타누 피. 페루말
사티시 케이. 포다라라
래드헤이 에스. 카우식
Original Assignee
사우스다코타주립대학
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사우스다코타주립대학 filed Critical 사우스다코타주립대학
Publication of KR20110036704A publication Critical patent/KR20110036704A/ko
Application granted granted Critical
Publication of KR101616771B1 publication Critical patent/KR101616771B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020107027648A 2008-05-09 2009-05-11 비면역원성의 소수성 단백질 나노입자의 형성방법 및 그 용도 Active KR101616771B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12713408P 2008-05-09 2008-05-09
US61/127,134 2008-05-09

Publications (2)

Publication Number Publication Date
KR20110036704A KR20110036704A (ko) 2011-04-08
KR101616771B1 true KR101616771B1 (ko) 2016-04-29

Family

ID=41264904

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107027648A Active KR101616771B1 (ko) 2008-05-09 2009-05-11 비면역원성의 소수성 단백질 나노입자의 형성방법 및 그 용도

Country Status (11)

Country Link
US (2) US8669225B2 (https=)
EP (1) EP2285825B1 (https=)
JP (2) JP5546532B2 (https=)
KR (1) KR101616771B1 (https=)
CN (1) CN102066399B (https=)
AU (1) AU2009244742B2 (https=)
BR (1) BRPI0908686B8 (https=)
CA (1) CA2723563C (https=)
IL (1) IL209155A (https=)
RU (1) RU2010146684A (https=)
WO (1) WO2009137112A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
US8697098B2 (en) 2011-02-25 2014-04-15 South Dakota State University Polymer conjugated protein micelles
US20140234420A1 (en) * 2008-05-09 2014-08-21 Omathanu P. Perumal Method of Treating Skin Disorders using Nanoscale Delivery Devices and Transdermal Enhancing Compositions
BRPI0908686B8 (pt) * 2008-05-09 2021-05-25 South Dakota State Univ método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
EP2376522A4 (en) 2008-11-16 2013-12-25 Univ Texas LOW VISCOSIS HIGHLY CONCENTRATED SUSPENSIONS
WO2012000757A1 (en) 2010-06-30 2012-01-05 Unilever Nv Particles comprising hydrophobic polymer and hydrophobic phenolic compound
PL2594140T3 (pl) * 2010-07-16 2019-09-30 Universidad De Navarra Nanocząstki do kapsułkowania związków, ich wytwarzanie i zastosowanie
CN102120823B (zh) * 2011-01-06 2016-08-03 鲁传华 水溶性玉米朊的合成及在药物制剂中的运用
BR112013021732B1 (pt) 2011-02-25 2021-11-30 South Dakota State University Micela estável e utilização da micela estável
EP2678007A4 (en) * 2011-02-25 2015-08-12 Univ South Dakota PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION
JP2014514275A (ja) * 2011-03-10 2014-06-19 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム タンパク質ナノ粒子分散系
JP6209517B2 (ja) * 2011-08-26 2017-10-04 ベコイ ナノメディシンズ リミテッドＶｅｃｏｙ Ｎａｎｏｍｅｄｉｃｉｎｅｓ Ｌｔｄ． 病原体を捕獲するための合成物および薬学的組成物
EP2625966A1 (en) 2012-02-13 2013-08-14 Bionanoplus, S.L. Nanoparticles comprising a vegetable hydrophobic protein and a water miscible non-volatile organic solvent and uses thereof
WO2014005299A1 (en) * 2012-07-04 2014-01-09 Empire Technology Development Llc Quantum dot-protein complexes, films, and methods of use
KR102045732B1 (ko) * 2012-12-28 2019-11-18 엘지디스플레이 주식회사 온도감응형 계면활성제를 이용한 수용성 나노입자의 제조방법
US20150150822A1 (en) * 2013-06-04 2015-06-04 South Dakota State University Novel core-shell nanoparticles for oral drug delivery
IL228528A (en) 2013-09-17 2015-01-29 Technion Res & Dev Foundation Potato-based nanoparticles
EP3204046A4 (en) * 2014-10-09 2018-08-08 Andreas Voigt Use of meso-and nanoporous material for surfactant trapping in nanoparticle suspensions
US11484505B2 (en) 2016-10-13 2022-11-01 Thomas Jefferson University Delivery compositions, and methods of making and using same
EP3639812A4 (en) 2017-06-02 2021-03-17 Teika Pharmaceutical Co., Ltd. SOLUBILIZED MICELLA CONSISTING OF A LOW SOLUBLE COMPONENT AND SOLUTION CONTAINING IT
TWI642685B (zh) * 2017-07-26 2018-12-01 中原大學 新穎胜肽及其應用
CN109432433A (zh) * 2018-10-30 2019-03-08 中国药科大学 一种纳米载体的制备方法和用途
CN109730976B (zh) * 2018-12-24 2020-06-09 华中科技大学 一种基于自由基氧化制备白蛋白纳米粒的方法
CN110251487B (zh) * 2019-08-01 2021-11-02 郑州大学 一种提高多西他赛载药量和口服生物利用度的醇溶蛋白纳米粒的制备方法及其应用
CN112121019B (zh) * 2020-09-23 2022-05-31 合肥工业大学 抗氧化型淀粉基糊精复合纳米颗粒及其制备方法与应用
CN115025054B (zh) * 2022-06-09 2023-12-22 四川普锐特药业有限公司 一种以乳铁蛋白为载体的纳米组合物的制备方法
CN116998582A (zh) * 2023-08-08 2023-11-07 扬州大学 一种高溶解度油料植物蛋白的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2236521A (en) 1937-08-12 1941-04-01 Zein Corp Of America Ink
US5330778A (en) 1988-09-19 1994-07-19 Opta Food Ingredients, Inc. Hydrophobic protein microparticles
WO1991006287A1 (en) * 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US5254673A (en) 1991-12-26 1993-10-19 Opta Food Ingredients, Inc. Purification of zein from corn gluten meal
IE80468B1 (en) * 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
MY153295A (en) * 2004-09-29 2015-01-29 Nestec Sa Nanoparticulated whey proteins
CN101415395B (zh) * 2006-03-29 2012-02-08 富士胶片株式会社 酪蛋白纳米粒子
EP2054036B1 (en) * 2006-07-24 2019-12-18 Singh-Broemer and Company, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
CN101485629B (zh) * 2008-01-16 2013-01-23 沈阳药科大学 一种给药系统及其制备方法
BRPI0908686B8 (pt) * 2008-05-09 2021-05-25 South Dakota State Univ método de produção de nanopartículas não-imunogênicas, nanopartícula não-imunogênica terapeuticamente ativa, composição terapêutica, uso de uma nanopartícula não-imunogênica e kit para a produção de nanopartículas não-imunogênicas
EP2678007A4 (en) * 2011-02-25 2015-08-12 Univ South Dakota PROTEIN NANOTRIER FOR TOPICAL ADMINISTRATION

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148251A1 (en) 2005-12-22 2007-06-28 Hossainy Syed F A Nanoparticle releasing medical devices

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Controlled Release, August 2006, VoI 114, No 2, Pages 242-250.
'Lipid vesicles and other colloids as drug carriers on the skin', Advanced Drug Delivery Reviews, March 2004, VoI 56, pages 675-711.

Also Published As

Publication number Publication date
HK1158221A1 (en) 2012-07-13
CN102066399A (zh) 2011-05-18
EP2285825A4 (en) 2012-11-28
US9616021B2 (en) 2017-04-11
KR20110036704A (ko) 2011-04-08
EP2285825A1 (en) 2011-02-23
AU2009244742A1 (en) 2009-11-12
BRPI0908686B8 (pt) 2021-05-25
EP2285825B1 (en) 2020-07-15
JP5546532B2 (ja) 2014-07-09
IL209155A0 (en) 2011-01-31
CA2723563C (en) 2017-12-12
US8669225B2 (en) 2014-03-11
JP2011519932A (ja) 2011-07-14
BRPI0908686B1 (pt) 2020-09-29
US20140308351A1 (en) 2014-10-16
JP5851550B2 (ja) 2016-02-03
CN102066399B (zh) 2014-11-26
AU2009244742B2 (en) 2014-11-06
US20110091565A1 (en) 2011-04-21
RU2010146684A (ru) 2012-06-20
IL209155A (en) 2016-07-31
CA2723563A1 (en) 2009-11-12
WO2009137112A1 (en) 2009-11-12
JP2014177474A (ja) 2014-09-25

Similar Documents

Publication Publication Date Title
KR101616771B1 (ko) 비면역원성의 소수성 단백질 나노입자의 형성방법 및 그 용도
Yang et al. Mesona chinensis polysaccharide/zein nanoparticles to improve the bioaccesibility and in vitro bioactivities of curcumin
Sailaja et al. Different techniques used for the preparation of nanoparticles using natural polymers and their application
US9233110B2 (en) Protein nanocarriers for topical delivery
Joseph et al. Galactoxyloglucan-modified nanocarriers of doxorubicin for improved tumor-targeted drug delivery with minimal toxicity
Chen et al. Co-encapsulation of curcumin and resveratrol in zein-bovine serum albumin nanoparticles using a pH-driven method
EP3372226B1 (en) Targeted hydrophobic anti-tumour drug nanoformulation and preparation method thereof
CN107669632A (zh) 一种药物载体、胶束、抗肿瘤和抗肿瘤细胞转移药物制剂、及其制备方法和用途
İlhan et al. Aquasomes: A novel platform for drug delivery
Al-Ani et al. Development of a nanostructured double-layer coated tablet based on polyethylene glycol/gelatin as a platform for hydrophobic molecules delivery
Ngwuluka et al. Natural polymers in micro-and nanoencapsulation for therapeutic and diagnostic applications: part II-polysaccharides and proteins
Chen et al. Fabrication of curcumin− loaded foxtail millet prolamin− based nanoparticle: Impact of curdlan sulfate on the particle properties
CN101653611B (zh) 一种白蛋白-阿霉素纳米制剂及其制备方法和应用
Song et al. Imidazolium-based ionic liquid-assisted preparation of nano-spheres loaded with bio-active peptides to decrease inflammation in an osteoarthritis model: ex vivo evaluations
JP4974533B2 (ja) ジスルフィド架橋したタンパク質ナノ粒子
Megha et al. Aquasomes: a promising delivery systems for poorly soluble bioactives
Wubuli et al. Enhancing oral bioavailability and immunostimulatory activity of Glycyrrhiza uralensis polysaccharides through PLGA nanoparticle delivery system
HK1158221B (en) Method of forming non-immunogenic hydrophobic protein nanoparticles and uses therefor
CN101068556B (zh) 富含胰岛素样生长因子的鹿茸纳米化制品及其制备方法
CN116726161A (zh) 一种负载抗原多肽的白蛋白递送系统及其制备方法和应用
Li Surface modifications that benefit protein‐based nanoparticles as vehicles for oral delivery of phenolic phytochemicals
van Nostrum et al. 11 th European Workshop on Particulate Systems in Nanomedicine
Shah et al. chitosan Nanoparticles

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20190211

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 11